FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...

Moderna has dosed the first subject in the US in its Phase III Nova 301 clinical trial of its investigational norovirus vaccine, mRNA-1403.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Muscle-sparing is particularly important in patients with heart failure as it is associated with higher mortality.

Pfizer (NYSE:PFE) has reduced its ownership in the British consumer healthcare giant Haleon (NYSE:HLN) to 15% from 22.6% by ...